Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Habu coagulotoxicity: Clinical implications of the functional diversification of Protobothrops snake venoms upon blood clotting factors.

Debono J, Bos MHA, Nouwens A, Ge L, Frank N, Kwok HF, Fry BG.

Toxicol In Vitro. 2018 Nov 22;55:62-74. doi: 10.1016/j.tiv.2018.11.008. [Epub ahead of print]

PMID:
30471431
2.

High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor.

Rietveld IM, Lijfering WM, le Cessie S, Bos MHA, Rosendaal FR, Reitsma PH, Cannegieter SC.

J Thromb Haemost. 2018 Nov 24. doi: 10.1111/jth.14343. [Epub ahead of print]

PMID:
30471183
3.

Elevated coagulation factor levels affect the tissue factor-threshold in thrombin generation.

Rietveld IM, Schreuder M, Reitsma PH, Bos MHA.

Thromb Res. 2018 Dec;172:104-109. doi: 10.1016/j.thromres.2018.10.020. Epub 2018 Oct 25.

PMID:
30408635
4.

Factor V levels and risk of venous thrombosis: The MEGA case-control study.

Rietveld IM, Bos MHA, Lijfering WM, Li-Gao R, Rosendaal FR, Reitsma PH, Cannegieter SC.

Res Pract Thromb Haemost. 2018 Apr 14;2(2):320-326. doi: 10.1002/rth2.12091. eCollection 2018 Apr.

5.

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.

Verhoef D, Visscher KM, Vosmeer CR, Cheung KL, Reitsma PH, Geerke DP, Bos MHA.

Nat Commun. 2017 Sep 13;8(1):528. doi: 10.1038/s41467-017-00647-9.

6.

Lipid levels and risk of venous thrombosis: results from the MEGA-study.

Morelli VM, Lijfering WM, Bos MHA, Rosendaal FR, Cannegieter SC.

Eur J Epidemiol. 2017 Aug;32(8):669-681. doi: 10.1007/s10654-017-0251-1. Epub 2017 May 24.

7.

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.

van Rein N, Lijfering WM, Bos MH, Herruer MH, Vermaas HW, van der Meer FJ, Reitsma PH.

PLoS One. 2016 Dec 9;11(12):e0164485. doi: 10.1371/journal.pone.0164485. eCollection 2016.

8.

Efficient expression of functional human coagulation factor IX in stably-transfected Drosophila melanogaster S2 cells; comparison with the mammalian CHO system.

Vatandoost J, Bos MH.

Biotechnol Lett. 2016 Oct;38(10):1691-8. doi: 10.1007/s10529-016-2156-6. Epub 2016 Aug 26.

PMID:
27565667
9.

Erratum to: Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line.

Khorshidi S, Zomorodipour A, Behmanesh M, Vatandoost J, Bos MH.

Biotechnol Lett. 2015 Oct;37(10):2097. doi: 10.1007/s10529-015-1909-y. No abstract available.

PMID:
26253300
10.

Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line.

Khorshidi S, Zomorodipour A, Behmanesh M, Vatandoost J, Bos MH.

Biotechnol Lett. 2015 Sep;37(9):1773-81. doi: 10.1007/s10529-015-1868-3. Epub 2015 Jun 24. Erratum in: Biotechnol Lett. 2015 Oct;37(10):2097.

PMID:
26105559
11.

Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity.

Kleinegris MC, Bos MH, Roest M, Henskens Y, Ten Cate-Hoek A, Van Deursen C, Spronk HM, Reitsma PH, De Groot PG, Ten Cate H, Koek G.

J Thromb Haemost. 2014 Oct;12(10):1647-57. doi: 10.1111/jth.12706. Epub 2014 Sep 30.

12.

Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides.

Bunce MW, Bos MH, Krishnaswamy S, Camire RM.

J Biol Chem. 2013 Oct 18;288(42):30151-60. doi: 10.1074/jbc.M113.506840. Epub 2013 Sep 6.

13.

A bipartite autoinhibitory region within the B-domain suppresses function in factor V.

Bos MH, Camire RM.

J Biol Chem. 2012 Jul 27;287(31):26342-51. doi: 10.1074/jbc.M112.377168. Epub 2012 Jun 15.

14.

Evolutionary conservation of the tissue factor disulfide bonds and identification of a possible oxidoreductase binding motif.

van den Hengel LG, van den Berg YW, Reitsma PH, Bos MH, Versteeg HH.

J Thromb Haemost. 2012 Jan;10(1):161-2. doi: 10.1111/j.1538-7836.2011.04556.x. No abstract available.

15.

Expression of biologically active human clotting factor IX in Drosophila S2 cells: γ-carboxylation of a human vitamin K-dependent protein by the insect enzyme.

Vatandoost J, Zomorodipour A, Sadeghizadeh M, Aliyari R, Bos MH, Ataei F.

Biotechnol Prog. 2012 Jan-Feb;28(1):45-51. doi: 10.1002/btpr.723. Epub 2011 Oct 19.

PMID:
22012919
16.
17.

Procoagulant adaptation of a blood coagulation prothrombinase-like enzyme complex in australian elapid venom.

Bos MH, Camire RM.

Toxins (Basel). 2010 Jun;2(6):1554-67. doi: 10.3390/toxins2061554. Epub 2010 Jun 18. Review.

18.

The molecular basis of factor V and VIII procofactor activation.

Camire RM, Bos MH.

J Thromb Haemost. 2009 Dec;7(12):1951-61. doi: 10.1111/j.1538-7836.2009.03622.x. Epub 2009 Sep 18. Review.

19.

Venom factor V from the common brown snake escapes hemostatic regulation through procoagulant adaptations.

Bos MH, Boltz M, St Pierre L, Masci PP, de Jersey J, Lavin MF, Camire RM.

Blood. 2009 Jul 16;114(3):686-92. doi: 10.1182/blood-2009-02-202663. Epub 2009 Apr 13.

20.

Two outbreaks of campylobacteriosis associated with the consumption of raw cows' milk.

Heuvelink AE, van Heerwaarden C, Zwartkruis-Nahuis A, Tilburg JJ, Bos MH, Heilmann FG, Hofhuis A, Hoekstra T, de Boer E.

Int J Food Microbiol. 2009 Aug 31;134(1-2):70-4. doi: 10.1016/j.ijfoodmicro.2008.12.026. Epub 2008 Dec 31.

PMID:
19167125

Supplemental Content

Support Center